Week In Review: BioKangtai Acquires China Rights To AstraZeneca's COVID-19 Vaccine

BioKangtai, a Guangdong vaccine company, in-licensed rights to develop, manufacture, and market AstraZeneca's COVID-19 vaccine in China. Biogen announced a $2 billion deal to partner Denali Therapeutics' potential Parkinson's Disease therapy.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
X